BMRN SCHEDULE 13G: SEC filing

BIOMARIN PHARMACEUTICAL INC

Filed with the SEC on · accession 0000905148-26-005116

BIOMARIN PHARMACEUTICAL INC (BMRN) filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 20, 2026. Viking Global Investors LP and affiliated entities filed an initial Schedule 13G reporting beneficial ownership of BioMarin Pharmaceutical common stock. The stock moved -1.6% by the first close after the filing.

Summary of the filing

Viking Global Investors LP and affiliated entities filed an initial Schedule 13G reporting beneficial ownership of BioMarin Pharmaceutical common stock. Their ownership briefly exceeded 5% on November 13, 2026, but subsequent dispositions reduced it to 4.8% by the November 20, 2026 filing date.

Key details

Shares beneficially owned by Viking Global Investors LP as of filing date$9.4M
Shares beneficially owned by Viking Global Investors LP as of November 13, 2026$9.7M
Reporting person / beneficial ownerViking Global Investors LP
IssuerBioMarin Pharmaceutical Inc.
Reporting person / affiliateViking Global Performance LLC
Reporting person / affiliateViking Global Equities II LP
Reporting person / affiliateViking Global Equities Master Ltd.
Reporting person / affiliateViking Long Fund GP LLC
Reporting person / affiliateViking Long Fund Master Ltd.
Reporting person / affiliateViking Global Opportunities Parent GP LLC
Reporting person / affiliateViking Global Opportunities GP LLC
Reporting person / affiliateViking Global Opportunities Portfolio GP LLC
Reporting person / affiliateViking Global Opportunities Liquid Portfolio Sub-Master LP
Reporting person / viking global investorsOle Andreas Halvorsen
Reporting person / viking global investorsRose Sharon Shabet

How BMRN stock reacted

Close before

$61.42

Nov 19, 2026

First close after

-1.61%

$60.43

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for BMRN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BMRN?

Click here

Frequently asked questions

What did BMRN file with the SEC on Nov 20, 2026?

BMRN filed a SCHEDULE 13G (SEC filing). Viking Global Investors LP and affiliated entities filed an initial Schedule 13G reporting beneficial ownership of BioMarin Pharmaceutical common stock. Their ownership briefly exceeded 5% on November 13, 2026, but subsequent dispositions reduced it to 4.8% by the November 20, 2026 filing date.

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did BMRN stock react to this filing?

BMRN closed at $61.42 before the filing and $60.43 on Nov 20, 2026 (-1.61%).

Other BMRN SEC filings

Get alerts when BMRN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days